Last reviewed · How we verify

Treatment Algorithm B

Alimentiv Inc. · FDA-approved active Biologic

Treatment Algorithm B is a clinical decision-support tool or therapeutic protocol developed by Alimentiv Inc. for gastrointestinal or digestive disorders.

At a glance

Generic nameTreatment Algorithm B
Also known asvedolizumab
SponsorAlimentiv Inc.
ModalityBiologic
Therapeutic areaGastroenterology
PhaseFDA-approved

Mechanism of action

As a marketed algorithm or treatment protocol rather than a traditional pharmaceutical compound, Treatment Algorithm B likely represents a structured clinical approach to diagnosis and management of gastrointestinal conditions. The specific mechanistic details are not publicly available in standard pharmaceutical databases, as it appears to be a proprietary clinical tool or care pathway rather than a drug with a defined molecular mechanism.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: